Trump FDA pressed to tighten abortion-pill safety after study points to dangers
The Washington Times
Valerie Richardson
Pressure is building on the Food and Drug Administration to reinstate safeguards on the abortion pill after a largest-of-its-kind study found the number of serious health scares far higher than the agency has previously acknowledged.
Congressional Republicans joined pro-life advocates in urging the agency to take a fresh look at the data after explosive research released last week showed that 10.93% of women who were prescribed mifepristone were treated within 45 days for conditions including sepsis and hemorrhaging.
That figure is 22 times higher than that on the drug’s warning label, which puts the adverse event rate at less than 0.5%, according to the Ethics and Public Policy Center study of 865,727 cases.